Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 08

418P - Colorectal cancer lung metastases resection and its impact on survival in the oligometastatic setting

Date

10 Sep 2022

Session

Poster session 08

Topics

Tumour Site

Colon and Rectal Cancer

Presenters

Jose Ruffinelli Rodriguez

Citation

Annals of Oncology (2022) 33 (suppl_7): S136-S196. 10.1016/annonc/annonc1048

Authors

J.C. Ruffinelli Rodriguez1, E. Guinó2, A. Ruiz Valderrama1, G. Ibañez3, I. Macia Vidueira4, S. Padrones Sanchez5, A. Navarro Martin6, C. Santos Vivas7

Author affiliations

  • 1 Medical Oncology Department, Catalan Institute of Oncology (ICO), IDIBELL, 08908 - L'Hospitalet de Llobregat, Barcelona/ES
  • 2 Cancer Prevention And Control Program, Catalan Institute of Oncology (ICO), IDIBELL, 08908 - L'Hospitalet de Llobregat, Barcelona/ES
  • 3 Gastroenterology, Hospital Universitari de Bellvitge, 08907 - Hospitalet de Llobregat/ES
  • 4 Thoracic Surgery, Hospital Universitari de Bellvitge, 08907 - Hospitalet de Llobregat/ES
  • 5 Pneumology, Hospital Universitari de Bellvitge, 08907 - Hospitalet de Llobregat/ES
  • 6 Radiation Oncology Department, ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), 08908 - Hospitalet de Llobregat/ES
  • 7 Medical Oncology Department, Catalan Institute of Oncology (ICO), Bellvitge Biomedical Research Institute (IDIBELL), CIBERONC, 08908 - L'Hospitalet de Llobregat/ES

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 418P

Background

Colorectal cancer lung metastases (CRLM) are a common form of newly diagnosed advanced disease and relapse after radical treatment (ttm) of early-stage tumours. In oligometastatic patients (pts), pulmonary resection is usually considered in some point of the multimodal ttm approach. Nevertheless, the real benefit of lung metastasectomy and perioperative chemotherapy in survival is in constant debate and strong prognostic factors are still lacking.

Methods

We performed a retrospective study to evaluate the clinical and pathological characteristics of a cohort of pts with CRLM assessed in a multidisciplinary tumour board, both synchronous and metachronous, to assess the role of surgical resection as part of oligometastatic disease local ttm and to identify prognostic factors. Demographic and clinicopathological data were collected and the impact of metastasectomy in disease outcome, with or without perioperative chemotherapy (PCT), was determined. Overall survival (OS) was estimated by Kaplan–Meier method.

Results

Of 270 pts registered between January 2012 and October 2020, 106 (39.2%) were suitable for surgical ttm. Median age at diagnosis was 64 years old (27-82) and 74 (69.8%) pts were male. Most frequent primary tumour location were rectum (44.2%) and sigmoid (36.5%). Metachronous CRLM were found in 84 pts (79.2%) and in 22 pts (20.8%) they were present at diagnosis. In early-stage pts, stage was pT1-2 (13.4%), pT3 (71.4%), pT4 (14.3%) and pN stage was N- in 38.1% and N+ in 60.9%. After a median follow-up of 78.2 months (mo), median overall survival (mOS) was 110.1 mo and significantly worse in pts with synchronous CRLM (82 vs 123.9 mo; p=0.04). In patients with CRLM as single site of first relapse (n=82) that underwent surgery as initial ttm, the number of CRLM showed prognostic impact with a HR of 5.18, p=0.03 (1 lesion mOS 123.9mo, 2-3 lesions mOS 110.1mo, ≥4 lesions mOS 80.7mo). In the 28 pts (34.1%) that received PCT we found no additional benefit in OS (HR 1.04, 95% CI 0.49-2.2;p=0.91).

Conclusions

Our results are consistent with historical data that show the value or surgical resection of CRLM as part of multidisciplinary approach, but also put into question the real impact of perioperative systemic treatment in improving survival.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.